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Atherosclerosis complicated by plaque rupture and superimposed thrombosis is primarily responsible
for acute coronary syndromes. Plaques most vulnerable to rupture contain a large extrac~ellular lipid-
rich core, thin afibrous cap with reduced collagen content and smooth muscle density and increased
numbers of activated macrophages. Macrophages have the ability to secrete proteolytic enzymes and
often infiltrate the region of imminent plaque rupture. Plaque disruption tends to occur at points where
a plaque surface is the weakest and coincides with points where biochemical and haemodynamic
stresses act on plaques. Reduced matrix synthesis as well as increased matrix degradation may
predispose fibrous caps to rupture spontaneously or in response to extrinsic mechanical or
hemodynamic stresses. Control of cholesterol levels and factors that produce endothelial injury may
result in plaque stabilization, prevent plaque rupture and ultimately lead to reduction in the frequency
of acute coronary syndromes. The concept of plaque stabilization seems plausible. Indirect data from
clinical trials involving hypocholestremic drugs and avoidance of risk factors provide strong support
for this new paradigm. Thus, plaque stabilization may prove to be an important modality for reduction
of lethal consequences of coronary atherosclerosis.
Introduction 
Atherosclerosis, global in distribution has reached epidemic proportions in the Western societies1-4.
Although clinically it may not be evident until middle age or later, atherosclerosis is considered to be a
slowly progressing and complex disease that begins in childhood5. It remains a leading cause of death,
carries serious morbidity and accounts for about one-third of all deaths ‘and two-thirds of deaths due to
cardiovascular complications6. Progression of this disease from a relatively benign state to a life-
threatening acute coronary syndrome depends on the type of plaque. The treatment of plaque disruption
with superimposed thrombosis requires an understanding of the pathophysiology of plaque rupture.
Recent advances in molecular pathology, coronary diagnostic techniques including pharmacotherapy of
cardiovascular disorders have opened up new windows to study the factors lead ing to plaque rupture.
This paper deals with the basic concept of atherosclerosis, its complications and pharmacological
interventions to reduce the consequences of atheromatous plaque rupture.
Epidemiology and risk factors
Atherosclerosis is most prevalent among the populations of North America, Europe, Australia, New
Zealand and Soviet Union. In contrast, it is much less common in central and South America, Africa,
Asia and the Orient. Epidemiological studies are indicative that advancing age, male gender and certain
genetic factors increase the risk of atherosclerosis (Table I).
This familial predisposition is most likely polygenic, in particular, the disorders like hyperlipidemia,
hypertension and diabetes mellitus. The risk factors that predispose to atherosclerosis and the resultant
ischaemic heart disease have been identified by a number of prospective studies, most notably, the
Framingham Study and the Multiple risk factor intervention trial7,8 as summarized in Table II.
The most important of these are hyperlipidaemia9,10, hypertension11 cigarette smoking12 and
diabetes13. Less pronounced and difficult to assess risk factors include, insufficient regular physical
activity, stress, obesity, use of oral contraceptives, hyperuricaemia, high carbohydrate intake and
hyperhomocysteinemia14. Demonstration of an epidemiologic association does not necessarily prove a
pathogenetic relationship, so the cause and pathogenesis of atherosclerosis remain subject of lively
speculation and controversy.
Pathogenesis
Atherosclerosis with plaque disruption or fissuring with superimposed thrombosis frequently
complicates its course. The importance of atherosclerosis has stimulated enormous efforts to investigate
its causes and a number of hypotheses for its pathogenesis have been proposed.
I. Response-to-injury hypothesis
Originally, traced back to von Rokitansky and Virchow15,16 and formally proposed in its current form
by Ross17,18, the lesions of atherosclerosis represent a chronic form of inflammatory fibro-proliferative
response of the arteial wall to various injuries stimuli19. This may be defensive response which
becomes the disease process itself. The hypothesis postulates that the initiating event in the atherogenic
process is some form of overt injury (oxidized cholesterol, cigarette smoke, homocystinemia,
catecholam ines, hyperglycaemia or hypertension) to the vascular intima which results in
morphologically detectable endothelial damage. Further investigation of this fibromuscular
proliferative phenomenon has revealed an abundance of cytokines, growth factors and other vasoactive
substances that cause vascular smooth muscle migration, proliferation and extracellular matrix
secretion. This process is considered to be mediated by platelet--derived growth factor, angiotensin,
thrombin, interleukin-l and tumour necrosis factor and a number of other factors15,16,19.
2. Endothelial injury and dysfunction
Although experimental denudation of the intimal lining is sufficient to elicit a complex response to
injury phenomenon, this form of mechanical damage is not relevant to natural atherosclerosis. Indeed,
early lesions of atherosclerosis in diet-induced animal models typically fail to reveal any overt
endothelial injury20. Endothelial dysfucntion, a phenotypic modulation to a non adaptive functional
state, might result in an imbalance between endothelial-dependent procoagulation and anticoagulation
mechanisms and may result in an acute, localized thrombotic event or a chronic thrombotic tendency of
the vessel wall. Endothelial dysfunction may also involve decreased production of endothelium-derived
relaxing factor (EDRF), resulting jn vasospastic tendency (vasoconstricti on, platelet aggregation,
vasospasm and thrombosis) as observed in early atherosclerosis21,22.
3. Endothelium-dependent mechanisms of leukocyte recruitment in atherosclerosis
During development of atherosclerosis, an important change in the endothelium is its modulation to a
proinflammatory state, with upregulation of cell surface adhesion molecules and chemo-attractant
factors that promote leukocyte recruitment and activation23. In fact, adherence of circulating blood
monocytes to the intact intimal surface of large arteries is the earliest morphologically detectable
cellular event in atherogenesis24. These cells migrate across the endothelium, tend to replicate and
become transformed into lipid-laden foam cells. In addition to accumulating cholesterol esters19, this
differentiating monocyte-macrophage population of cells can cause progression of lesions through local
generation of cytokines, growth factors, procoagulant and fibrinolytic components, eicosanoids and
toxic oxygen products. Leukocyte-selective nature of this mononuclear recruitment is suggestive of
endothelium-dependent adhesion mechanisms which are analogous to those recently described in acute
and chronic inflammation25. These observations have led to the hypothesis that these localized
mononuclear leukocyte-endothelial interactions reflect specific molecular changes in the adhesive
properties of the endothelial surface. This in turn may involve inducible endothelial-leukocyte adhesion
molecules (ELAMS) Expressed in atherosclerotic lesions26.
Immunohistochernical studies have localized the expression of these molecules at various stages of
atherosclerotic lesion development in experimental animals and in some instances in humans27. The
relative contributions of these mechanisms of leukocyte recruitment to the atherogenic process is an
area of ongoing study that has important pathogenetic as well as therapeutic opportunities.
Morphology
Fatty streaks: Fatty streaks, the earliest lesion of atherosclerosis, are not significantly raised and do not
cause any disturbance in blood flow. However, they may be the precursors of the more ominous
atheromatous plaques28. Fatty streaks begin as multiple yellow flat spots and are composed of lipid-
filled foam cells. Extracellular lipids are present in relatively smaller amounts than in plaques and
proteoglycans, collagen and elastic fibres are found in variable amounts29. Fatty streaks have been seen
in aortas of very young children (<1 year) and in all children older than ten years, regardless of
geography, race, sex, or environment. Whatever the outcome of a specific fatty streak, the prevalence
of these lesions early in life emphasize that atherosclerosis has its roots at a ery young age6.
Atheromatous plaques
Focal intimal thickening and lipid accumulation produce the characteristic atheromatous plaques. Three
principal components of atheromatous plaques are, cells (smooth muscle cells, macrophages and
leukocytes), connective tissue extracellular matrix (collagen, elastic fibres and proteoglycans) and lipid
deposits (intracellular and extracellular). These components occur in varying proportions in different
plaques, giving rise to a spectrum of lesions. Usually, the superficial fibrous cap is composed of smooth
muscle cells with a few leukocytes and relatively dense connective tissue. A cellular area beneath and
to the side of the cap (the shoulder) consists of a mixture of macrophages, smooth muscle cells and T
lymphocytes. A deeper necrotic core with disorganized mass of lipid material, cholesterol clefts,
cellular debris, lipid-laden foam cells, fibrin, plasma proteins and a thrombus at various stages of
organization30-32. The type of lipid found in plaques is primarily cholesterol.. The cholesterol esters
and calcification appears to be related to the severity of stenosis and the age of the patient33. However,
the composition of atheromas can vary, not only between different persons but also between arteries in
the same person, same organ and even within same artery itself, affecting the vascular compliance34.
Soft atheromas consist of necrotic debris whereas hard plaques usually present rigid fibrocalcific
structures and can be designated as fatty, fibrofatty or fibrous based on relative contribution by soft and
firm structural components (Figure 1).

Unstable atherosclerotic plaques
Numerous studies have demonstrated that coronary thrombosis, the immediate cause of acute coronary
syndromes is a consequence of plaque disruption35. Stable plaques may become unstable lesions when
dynamic alterations occur which directly or indirectly lead to luminal narrowing. The four most
frequently encountered alterations are plaque rupture, plaque hemorrhage, thrombosis and medial
spasm (Figure 2). It has been shown that these alterations generally act in concert36,37. Furthermore,
plaque rupture often results in thrombosis and through the release of various mediators, promote
thrombosis. This is turn, may cause mechanical stresses that extent the size of plaque rupture and the
cycle continues37.
Plaque rupture
The causes of plaque rupture are complex as given in Table11,38,39.
Numerous clinico-pathologic studies have shown that surface injury is the most common feature of
unstable plaques, ranging from minimal surface erosions to lacerations that extend deep within the
plaque38,40. Regardless of the extent of injury, it results in exposure of the luminal blood to
thrombogenic surface, thereby setting the stage of acute thrombotic obstruction. The consequences of
plaque rupture depend upon the extent of thrombus formation and may result in unstable angina, acute
myocardial infarction or sudden death. Plaque rupture has been associated with a trigger event in about
half of the patients with myocardial infarction41,42. Physical exertion and emotional stress can trigger
plaque disruption by surges in sympathetic activity with an increase in blood pressure, pulse pressure,
blood flow, heart rate and coronary tone42. Vasospasm, in itself can produce endothelial damage and
patients are more likely to have a secondary myocardial infarction who suffer vasospasm during
cardiac catheterization
Prevention of plaque rupture
During management of patients with coronary artery disease, a reasonable goat is to prevent
destabilization of coronary plaques. If this goal cannot be accomplished, then a second option is to
counteract thrombus formation. Current efforts to prevent acute ischaernic syndromes have been
limited by our inability to identify those plaques prospectively which are prone to rupture. The
development of intravascular ultrasound has allowed the assessment of plaque morphology and
composition45. However, at present no technology exists that can discriminate a plaque that will
rupture from those with least tendency to rupture. Application of nuclear magnetic resonance
microscopy may allow non-invasive assessment of atherosclerotic plaque in future46 but studies have
shown that the vulnerability of plaque to disruption appears to be determined by the presence of a
dense lipid-rich core, a thin fibrous cap and an inflammatory cellular infiltrate rather than by the size of
the plaque or the severity of stenosis35.
Pharmacologic interventions
Once a vulnerable plaque is identified, antilipodaemic drug therapy, antioxidants (vitamins E, C), B-
adrenoceptor blockers, angiotensin-converting enzyme inhibitors and thrombolytic therapy can be used
to reduce the incidence of plaque rupture apart from elimination of risk factors. Some regression of
atherosclerosis has been shown to substantially reduce the incidence of myocardial infarction, unstable
angina and cardiac death47.
Hypolipidaemic theory: Low density lipoprotein (LDL) is oxidized in vascular endothelial cells to a
highly injurious product that results in characteristic cell dysfunction (loss of dilation, constriction,
thrombosis and inflammation), before and during the development of atherosclerosis, in particular
during plaque rupture48,49. During the several decades, studies have focused on the effects of serum
lipids on atherogenesis50. There is strong evidence in recent trials on patients showing that treatment of
serum lipids can improve clinical outcomes (e.g. acute coronary events) in 18 months to 3 years49,51.
Lowering of total serum cholesterol, low-density lipoproteins, cholesterol and triglycerides, as well as
increasing high-density lipoprotein cholesterol can be achieved with anticholesterolemic drugs52.
Aggressive lipid lowering regimens have demonstrated an alteration in the progression of established
atherosclerosis and regression of atheroma in some patients. A significant reduction in cardiac events in
these studies have been thought to be related with plaque stabilization and restoration of endothelial
vasodi lation50-52. Therapeutic lowering of serum cholesterol, LDL and oxidized LDL have recently
been shown to improve endothelium-dependent dilation in the forearm vasculature of patients with
hypercholesterolemia53. These observations are interesting because they show that atherogenic lipids
can interact with blood vessel function even more rapidly than previously suspected. This study also
shows that the relationship between atherogenic lipids and vascular dysfunction is dynamic and subject
to change within minutes. This finding has important implications regarding the pathogenesis of
ischemic syndromes and use of potent and rapidly acting lipid-lowering therapies in patients53.
B-Adrenoceptor blockers
B-adrenoceptor and calcium channel blockers have been commonly used as first-line therapy for
treatment of hypertension for more than two decades now. Statistically significant and clinically
relevant reductions of mortality and reinfarction have been shown in prospective, double-blind,
placebo-controlled trials54,55. Experimental studies suggest that beta blockers may have
antiatheroscierotic effect in animals fed on atherogenic diet and subjected to stress54. There is
substantial evidence that B-adrenoceptor blockers reduce the incidence of plaque rupture by reducing
circumferential plaque stress as a result of reduction in blood pressure and blunting hypertensive
pressure surges. B-adrenoceptor blockers increase plaque tensile strength by reducing heart rate and
may also prevent plaque rupture by increasing the ability of the plaque’s fibrous cap to withstand
stress54-56.
Angiotensin-converting enzyme inhibitors
Angiotensin II is a growth factor for vascular smooth muscle cells and may play a role in the initiation
of plaque rupture. A strong association between vascular angiotensin generation and the development
of coronary atherosclerosis in humans has been found using immunohistochem ical techniques57.
Angiotens in converting enzyme (ACE) in hypercellular lesions, atheromatous plaques and ruptured
plaques contributes to the further progression of atherosclerosis via an increase in vascular angiotensin
11 formation and inactivation of bradykinin58.
Recent studies have shown an effect of ACE inhibition on the development of atherosclerosis in animal
models. Captopril and Cilazpril prevent myointimal proliferation after vascular injury in rat. Captopril
reduces aortic cholesterol content and percentage intimal aortic surface covered by lesions in Watanabe
heritable hyperlipidemic rabbits. Captopril also significantly reduces the progression of carotid and
coronary lesion in monkeys fed a high cholesterol diet59. The clinical usefulness of ACE-inhibitors in
preventing the recurrence of myocardial infarction had been observed in large randomized trials.
Results from these studies have suggested that ACE-inhibitors show vasculoprotective effects, possibly
by preventing angiotension II induced vascular proliferation and therefore suppressing the development
of atherosclerosis60,61. It is also conceivable that the blood pressure effects of ACE-inhibitors could
play a role in the antiatherosclerotic effects shown by these drugs59.
Antioxidants: There is mounting evidence that oxidation of low-density lipoprotein cholesterol may be
instrumental in atherogenesis. Oxidized LDL is an initiator of macrophage accumulation within the
plaque. A number of studies have been undertaken to evaluate the effects of antioxidants vitamins, beta
carotene and selenium on coronary artery disease. Results in many instances have been promising,
particularly in case of vitamin E supplements62. It is thought that the antioxidants inhibit the formation
of oxidized LDL63,64.
Anticoagulation therapy
The coagulation system is activated in vivo by exposure to tissue factors. This occurs when
atherosclerotic plaque ruptures or when the endotheliurn is damaged by angioplasty. Endogenous
thrombin is a major trigger for thrombosis in acute coronary syndromes38,39. Heparin is a potent
inhibitor of thrombin and thrombin generation but its ability to accelerate thrombolysis is relatively
limited clinically. Use of aspirin is most impressive in the early stages of symptomatic unstable
coronary artery disease, a period when prothrombotic forces are most apparent65. When added to the B-
adrenoceptor blocker-based treatment of patients with stable angina pectoris, aspirin significantly
decreases the likelihood of developing fatal as well as non- fatal myocardial infarction66.
Aspirin remains as the first line anti-platelet drug. Other approaches involving glycoprotein (GP) lIb-
Illa antagonists block the GP lIb-IlIa integrin receptor for fibrinogen, the final pathway to platelet-
platelet bridges, irrespective of the causative stimulus and cause considerably more effective inhibition
of platelet aggregation than induced by aspirin. At present, only tested with regard to ischaemic events
in patients undergoing high-risk angioplasty, these compounds (abciximab, integrilin, tirofiban) reduce
such events by approximately 35%67. The possible value of these drugs and their feasibility for long-
term use in patients prone to unstable coronary events remain to be established68.
Molecular Biology
Recent studies have shown that p53, a gene regulator protein which stimulates the transcription of a
gene encoding cyclin-dependent kinase inhibitor protein called p21, is involved in the control of
proliferation of human vascular smooth muscle cells (VSMCs) in atheromatous plaques. It has been
demonstrated that VSMCs undergo apoptosis in the human atheromatous plaques, particularly at areas
prone to rupture, suggesting that VSMC apoptosis may promote plaque rupture and subsequent
thrombosis leading to myocardial infarction69,70.
More recent studies have suggested that many plaque cells are in a process of apoptosis as determined
by positive deoxyribonucleotide-transferase-mediated dUTP end labelling71. With the advent of
molecular biology techniques, it has now become possible to clone differentially expressed genes in
vessels with or without atherosclerosis. This would help to characterize the molecular and cellular
mechanisms of this disease. In addition, the search for such candidate genes could form the basis of
future genetic interventions during the development of atherosclerosis.
Conclusion 
Plaque rupture is usually the initial event in the formation of coronary thrombi, responsible for acute
coronary syndromes. From the present discussion, it can be speculated that to prevent or minimize the
development of atherosclerosis, the elimination or control of chronic risk factors is important. Once the
disease is symptomatic, drug therapy is generally directed towards relieving the obstruction and
prevention of plaque rupture and its complications. Further insight into the causes of plaque rupture
may provide information regarding the prevention of disease. The current research and treatment
modalities are directed towards understanding and controlling the risk
factors for acute plaque rupture and ultimately transformation of unstable plaques into stable and
quiescent lesions72.
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